Hidradenitis suppurativa (HS) is an inflammatory skin disease with poorly understood immunopathogenic mechanisms. LL-37 is an antimicrobial peptide, which is transcribed from the CAMP (cathelicidin antimicrobial peptide) gene. Previous reports showed upregulated levels of CAMP and LL-37 in HS lesions, and therefore, the aim of this study was to compare levels of LL-37 in HS to other inflammatory skin diseases and to establish immunomodulatory functions of LL-37 in HS. We confirm an upregulation of the LL-37 peptide in lesional HS skin with comparable levels as in psoriasis patients and are able to positively correlate the presence of LL-37 in HS with the presence of T cells, macrophages, neutrophils, IFN-γ, IL-17, IL-23, TNF-α, IL-32 and IL-1β.
| INTRODUCTION
Hidradenitis suppurativa (HS), also termed acne inversa, is a chronic inflammatory disease of the apocrine gland-bearing skin. HS lowers the quality of life of affected patients to a higher degree than other inflammatory skin diseases and is characterised by painful subcutaneous nodules in the axillary, inguinal and anogenital regions of the body. [1, 2] These nodules can progress into deep dermal abscesses with sinuses and fistula, accompanied by malodorous suppuration. [2] Efficient therapy of this recalcitrant disease is highly challenging due to the poor understanding of the involved pathogenetic mechanisms. Nowadays, the trigger for HS is thought to be hyperkeratinisation of the hair follicle, which leads to distention and rupture of the pilosebaceous unit, leading to an infiltration of inflammatory cells with a subsequent dysregulation of the immune system. [3, 4] LL-37 is the only mature human antimicrobial peptide (AMP) of the cathelicidin family and is transcribed and processed from the CAMP gene. It has an alpha-helical and amphipathic structure, which enables LL-37 to kill bacteria. [5, 6] LL-37 is produced by activated tissue resident cells such as keratinocytes and epithelial cells (ECs), but also by innate and adaptive immune cells, such as neutrophils, macrophages, T cells and B cells. [7] [8] [9] [10] [11] [12] [13] Next to its antimicrobial function, LL-37 is also a potent immunoregulator. LL-37 is a chemoattractant for CD4 + T cells [10] , and in vitro LL-37-stimulated dendritic cells upregulate co-stimulatory molecules and increase the production of TNF-α, IL-6 and IL-12, which leads to the induction of a Th1/Th17 phenotype in T cells. [14] [15] [16] Moreover, in human peripheral blood mononuclear cells (PBMCs), LL-37 enhances certain pro-inflammatory responses in synergy with IL-1β, such as an increased production of CCL2, CCL7, CXCL-8 and IL-6. [17] Furthermore, LL-37 has an impact on cell proliferation in angiogenesis and wound healing and regulates hair growth. [18] [19] [20] LL-37 also promotes the establishment of several chronic inflammatory diseases such as obesity, insulin resistance and atherosclerosis. [21, 22] In PS, LL-37 is upregulated and some patients even possess autoreactive skin-homing T cells, which can recognise LL-37. [9, 23] In contrast to psoriasis (PS) patients, atopic dermatitis (AD) patients have decreased serum levels of LL-37. [24] These low levels could be attributed to high IL-10 levels, which suppress the induction of LL-37. [25] In HS, elevated CAMP and LL-37 levels have been reported, [26, 27] which were found to be produced by ECs around inflamed hair follicles in the outer root sheath and in the adjacent apocrine sweat glands. [27] Due to these results in the literature, we sought to further delineate the role of LL-37 in HS by comparing its levels to other are known to be elevated in HS [28] [29] [30] [31] [32] [33] [34] [35] correlate with the presence of LL-37. To complete our analysis, we investigated the impact of LL-37 on the proliferation of lectin-stimulated CD4 + and CD8 + T cells isolated from the blood of healthy donors and patients with HS and delineated by calcium assay, how LL-37 impacts proliferation of T cells directly.
| MATERIAL AND METHODS

| Samples from patients
The design of this study followed the Declaration of Helsinki pro- After isolation, PBMCs were immediately frozen and stored at −80°C in foetal calf serum (FCS) (Biochrom, Berlin, Germany) + 10% dimethyl sulphoxide (DMSO) (Sigma Aldrich, St. Louis, USA).
| Immunohistochemical staining
Immunostaining was performed as previously described. [28] In brief, with the secondary antibody. To determine the score for the presence of LL-37, CD3, CD66b and CD68 sections were analysed for stained cell density and cell distribution across the biopsy. The allocation of a semi-quantitative score was attributed as previously described, [36] using the following scale (in steps of 0.5): 0 = absent, 1 = weak/low expression with little distribution, 2 = moderate expression with intermediate distribution, 3 = strong expression with wide distribution.
| RNA isolation, complementary DNA synthesis and semi-quantitative real-time PCR analysis
As previously described, [28] OCT-embedded biopsies were cut into 10-μm sections, before the RNA was extracted with the help of the RNeasy lipid tissue mini kit (Qiagen, Valencia, USA).
A RNase-free DNase step removed contaminating DNA (Qiagen). Sequence Detector System (Applied Biosystems) as described in
Ref. [28] The final results are expressed as fold differences. These differences were calculated with the 2 −ΔΔCT method. The threshold cycle (CT) for the reference genes was determined using the geometric mean of the CT of the three reference genes, see Ref. [37] In samples where no CT-value was detected, CT-value was set to 40, as previously described.
[38] 
| Proliferation assay
| Calcium influx assay
Calcium influx measurements were assessed as described previously. [39] Briefly, PHA blasts, generated from healthy PBMCs in the presence of 50 IU/mL IL-2 (Roche, Basel, Switzerland) and PHA, 
| Statistical analysis
Statistical analysis was performed with GraphPad Prism software was considered statistically significant; P < .05 = *, P < .01 = **, P < .001 = ***.
| RESULTS
| LL-37 peptide is expressed in lesional HS skin
LL-37 expression was immunohistochemically analysed on tissue sections of lesional HS skin. As a comparison, lesional skin from AD and PS patients and healthy skin were assessed. Figure 1A -D shows representative examples of LL-37 staining in cryo-cut tissues, and the semi-quantitative analysis of these stainings is presented in Figure 1E . 
| In HS, CAMP mRNA levels do not always correspond to LL-37 peptide levels
After determining that LL-37 expression was increased in lesional HS skin, we sought to investigate whether these peptide levels correspond 
| LL-37 drives the proliferation of T cells in the presence of an unspecific activation independent of antigen-presenting cells via an increased calcium influx
To investigate the immunomodulatory role of LL-37 in patients with HS, we focused on the impact of LL-37 on the proliferation of both Figure 4C-D) . We could conclude that the proliferation enhancement was a direct effect of LL-37 on stimulated T cells.
To figure out how this effect is mediated, we measured the calcium influx in PHA blasts, which were stimulated with PHA alone or with PHA in the presence of increasing concentrations of LL-37 ( Figure 4E ).
Indeed, we were able to detect a more prominent increase in the calcium influx in the presence of PHA and LL-37 compared to PHA only. and IL-1β (r S = .68). Ct-values of mRNA analysis were normalised with housekeeping genes HPRT-1, GAPDH and B2M to healthy skin (=1); n(HS) = 24. Significance of correlation was determined with the Spearman's rank correlation coefficient (r S ) with* indicating a P-value < .05, ** indicating a P-value < .01 and *** indicating a P-value < .001
| DISCUSSION
Here, we show that LL-37 is upregulated on the peptide level in skin lesions of patients suffering from the recalcitrant skin disease HS, as already indicated by Emelianov et al [27] On the CAMP mRNA level,
we report an upregulation in PS, while no differences to healthy skin could be detected in AD skin. In HS, we cannot completely confirm Bechara et al's mRNA results, [26] as we only describe a mean four times increase in HS compared to healthy skin, but do not detect any statistically significant upregulation. By correlating peptide and mRNA levels, we were able to determine that LL-37 and CAMP do not correspond in all HS biopsies. This suggests that in some HS le- pro-inflammatory loops in lesional HS skin. Moreover, we report that in the presence of PHA, LL-37 drives CD4 + T-cell proliferation independent of APC help. However, in contrast to PS patients, as it was described by Lande et al, [23] we never detected any proliferation of T cells from patients with HS in the presence of LL-37 alone ( Figure S2 ).
The proliferative effect was found to be mediated by an additional influx of calcium into the T cells after a co-stimulation with PHA and LL-37. Interestingly, the calcium influx after PHA+LL-37 starts earlier than with PHA alone, suggesting that LL-37 mediates its effect directly via the membrane and is not receptor mediated, which has already been a suggested mechanism in the literature. [40] The question why LL-37 has a more prominent impact on the proliferation of CD4 + T cells remains. It was reported that LL-37 induces apoptosis in stimulated mouse CD8 + T cells, which could counter-regulate this pro-proliferative effect. [41] Concerning the role of LL-37 in HS pathogenesis, we hypothesise that LL-37 is present in early lesions, but then also remains high in the chronic phase, becoming a driver of the pro-inflammatory cascade. The arguments in favour of this hypothesis are that LL-37 is mainly produced by neutrophils, which enter the lesional skin early after initiation of inflammation where LL-37 mainly exerts its antimicrobial function. What is more, the presence of LL-37 also coincides with T cells and macrophages, which enter HS lesions at a later stage, and under the influence of LL-37 and other mediators, they may start producing Th1/Th17 cytokines, further driving the pro-inflammatory process. [42] Taken together, we report that LL-37 is upregulated in patients with HS and that its presence correlates with other pro-inflammatory mediators, such as Th1/Th17 cytokines. Further investigation of the involvement of LL-37 in immunomodulation showed that LL-37 and an unspecific activation lead to an APC independent boost of the proliferation of CD4 + T cells via direct calcium signalling. More insight is needed to understand pathological mechanisms in HS and to understand the role of LL-37 in this process, which could pave the way for future treatment possibilities by blocking LL-37 in this recalcitrant skin disease.
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